本帖最后由 老马 于 2013-3-13 13:43 编辑
. x+ M L: U2 E# V& d
) C* \) i# s0 }8 V8 a1 }健择(吉西他滨)+顺铂+阿瓦斯汀+ z4 l$ |6 u) a, |8 [5 n' k' U
Gemzar +Cisplatin + Avastin
8 x5 t& c0 C' [9 L$ b4 Hhttp://annonc.oxfordjournals.org/content/21/9/1804.full
- h$ Z2 \) O4 V0 ZOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : ?& H$ i( t7 D- `5 F( a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 r9 f1 G9 ^% @Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. : S) E5 ~. U }
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1054)
/ L) [* E* D* C9 X0 y$ D4 b4 ~
华为网盘附件:
4 G- @% J. Y! B$ k9 ]% R% Z【华为网盘】ava.JPG
6 T* V8 T8 d7 @7 @7 }; h$ o |